OCS vs. CPRX, GLPG, AGIO, PTGX, ZLAB, KROS, GPCR, SNDX, HRMY, and NAMS
Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Keros Therapeutics (KROS), Structure Therapeutics (GPCR), Syndax Pharmaceuticals (SNDX), Harmony Biosciences (HRMY), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Catalyst Pharmaceuticals received 464 more outperform votes than Oculis when rated by MarketBeat users. However, 86.36% of users gave Oculis an outperform vote while only 74.31% of users gave Catalyst Pharmaceuticals an outperform vote.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of -6,712.02%. Oculis' return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Catalyst Pharmaceuticals currently has a consensus target price of $26.71, suggesting a potential upside of 65.21%. Oculis has a consensus target price of $30.17, suggesting a potential upside of 156.52%. Given Catalyst Pharmaceuticals' higher probable upside, analysts plainly believe Oculis is more favorable than Catalyst Pharmaceuticals.
In the previous week, Oculis had 5 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 8 mentions for Oculis and 3 mentions for Catalyst Pharmaceuticals. Oculis' average media sentiment score of 0.63 beat Catalyst Pharmaceuticals' score of 0.35 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.
79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Catalyst Pharmaceuticals has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Catalyst Pharmaceuticals beats Oculis on 12 of the 17 factors compared between the two stocks.
Get Oculis News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
